| __timestamp | Bausch Health Companies Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 34916000 |
| Thursday, January 1, 2015 | 2682700000 | 36949000 |
| Friday, January 1, 2016 | 2810000000 | 45240000 |
| Sunday, January 1, 2017 | 2582000000 | 62416000 |
| Monday, January 1, 2018 | 2473000000 | 81289000 |
| Tuesday, January 1, 2019 | 2554000000 | 100359000 |
| Wednesday, January 1, 2020 | 2367000000 | 105326000 |
| Friday, January 1, 2021 | 2624000000 | 122356000 |
| Saturday, January 1, 2022 | 2625000000 | 152848000 |
| Sunday, January 1, 2023 | 2917000000 | 184259000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and Bausch Health Companies Inc. over the past decade. From 2014 to 2023, Bausch Health consistently reported higher SG&A expenses, peaking at approximately $2.9 billion in 2023, reflecting a 44% increase from 2014. In contrast, Corcept Therapeutics, while starting with a modest $35 million in 2014, saw a significant rise to $184 million by 2023, marking a staggering 426% growth. This trend highlights Corcept's aggressive expansion strategy, while Bausch Health's steady increase suggests a focus on maintaining its market position. These insights provide a window into the strategic priorities of these companies, offering valuable lessons for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?